Closed · RFA-DA-21-015 · CFDA 93.279 · Discretionary
Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R41/R42 - Clinical Trials Optional)
Federal grant opportunity posted by National Institutes of Health, cataloged on Grants.gov.
- up to $257K
- Award range
- Closed
- Status
- February 26, 2021
- Close date
- -
- Expected awards
The verdict
Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R41/R42 - Clinical Trials Optional) is a closed discretionary listing from National Institutes of Health that offered Up to $256,580. Future funding cycles may be published under the same CFDA number.
- up to $257K
- award range
- Closed
- application status
- 93.279
- CFDA program
Opportunity snapshot. This Grants.gov announcement - Novel Approaches to Decrease Stigma of Substance Use Disorders in order to Facilitate Prevention, Treatment, and Support During Recovery (R41/R42 - Clinical Trials Optional) - is cataloged under number RFA-DA-21-015 and tied to CFDA assistance listing 93.279, posted by National Institutes of Health. Grants.gov currently shows the opportunity as closed, first posted on December 23, 2020. The funding category is Discretionary, delivered as a grant.
Award economics. The award range on file is Up to $256,580. The agency has projected $2.0 million in total estimated funding for this announcement. Cost sharing is not required, so applicants do not need to commit matching funds to be competitive on this opportunity. Federal award ranges are often upper bounds; actual allocations reflect program appropriations, the strength of the applicant pool, and the evaluation committee's scoring.
Deadline and action path. This opportunity closed on February 26, 2021. Future funding cycles may be published under the same CFDA number, so monitoring the parent program page is the most reliable way to catch re-announcements. Every Grants.gov submission requires an active SAM.gov registration and a Unique Entity ID. Review the Eligibility section below carefully, federal eligibility categories (nonprofit, state or local government, tribal, individual, educational institution, small business) have distinct registration and reporting requirements. Pre-application outreach to the listed agency contact is permitted and often welcomed, it helps clarify scope and scoring priorities. Before acting on the deadline or award figures above, verify them directly on the official Grants.gov listing, amendments can change dates and amounts after this page was last refreshed.
Award Range
Up to $256,580
Close Date
February 26, 2021
Posted
December 23, 2020
Est. Total Funding
$2,000,000
Instrument
Grant
Description
The purpose of this Funding Opportunity Announcement is to support research applications for commercializable products aimed at reducing stigma around substance use disorders (SUD). Phase I applications are invited to develop and evaluate feasibility of novel digital technologies, services or other interventions to reduce stigma towards SUD in clinical care, including HIV prevention and care settings, clinical training and other relevant settings, and to establish methods to measure stigma reduction. Phase II applications are invited to demonstrate efficacy in decreasing stigma towards SUD and commercialization potential of these products in clinical care, training, and/or other relevant settings, including those providing HIV prevention and care with the goal to remove barriers to SUD prevention, treatment, and support during recovery. Phase II applications focused on HIV prevention and care settings are invited to demonstrate efficacy in decreasing stigma towards SUD and improving health outcomes for people living with HIV and SUD.
Eligibility
Grants.gov lists this opportunity under eligibility category code 23. These codes correspond to applicant types (state/local government, tribal organization, nonprofit, educational institution, individual, small business, etc.) defined in Grants.gov's own eligibility reference. See the current Grants.gov eligibility categories or check the official listing below for this opportunity's exact eligibility statement.
Official Listing on Grants.gov
View full details, application forms, and submission instructions.
Parent Grant Program
Drug Abuse Research Programs
National Institutes of Health
Agency Contact
NIH OER Webmaster FBOWebmaster@OD.NIH.GOV
Key Dates
Frequently Asked Questions
What is this grant opportunity?
Is this opportunity still open?
How much funding is available?
How do I apply?
More from National Institutes of Health
Validation Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U54 Clinical Trials Not Allowed)
Logistics Center for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U24 Clinical Trials Not Allowed)
Development and Testing of a Multi-use Frameworks Playbook for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (U01 Clinical Trial Not Allowed)
PRIMED-AI: Data-to-Model Academic-Industrial Partnerships (D2M-AIP) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (UG3/UH3 Clinical Trial Optional)
Model-to-Clinic (M2C) for Precision Medicine with AI: Integrating Imaging with Multimodal Data (PRIMED-AI) (UG3/UH3, Clinical Trial Optional)
Disclaimer: This information is sourced from Grants.gov and SAM.gov and is for informational purposes only. Opportunity details, deadlines, and eligibility requirements change frequently. Always verify current information directly on Grants.gov before applying. PlainGrants is not affiliated with any federal agency.
Read our methodology - how this data is sourced, computed, and verified.
Related
| Publisher | PlainGrants |
| Sources | the SAM.gov Assistance Listings and Grants.gov |